- Home
- BCDA vs PAVM Comparison
BCDA vs PAVM Comparison
Compare BCDA & PAVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- PAVM
- Stock Information
- Founded
- BCDA N/A
- PAVM 2014
- Country
- BCDA United States
- PAVM United States
- Employees
- BCDA N/A
- PAVM N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- PAVM Medical/Dental Instruments
- Sector
- BCDA Health Care
- PAVM Health Care
- Exchange
- BCDA Nasdaq
- PAVM Nasdaq
- Market Cap
- BCDA 11.0M
- PAVM 12.0M
- IPO Year
- BCDA N/A
- PAVM 2016
- Fundamental
- Price
- BCDA $2.12
- PAVM $0.60
- Analyst Decision
- BCDA Strong Buy
- PAVM Strong Buy
- Analyst Count
- BCDA 1
- PAVM 1
- Target Price
- BCDA $25.00
- PAVM $19.00
- AVG Volume (30 Days)
- BCDA 204.0K
- PAVM 149.7K
- Earning Date
- BCDA 08-12-2025
- PAVM 08-11-2025
- Dividend Yield
- BCDA N/A
- PAVM N/A
- EPS Growth
- BCDA N/A
- PAVM N/A
- EPS
- BCDA N/A
- PAVM 0.96
- Revenue
- BCDA $3,000.00
- PAVM $1,993,000.00
- Revenue This Year
- BCDA N/A
- PAVM N/A
- Revenue Next Year
- BCDA N/A
- PAVM $455.63
- P/E Ratio
- BCDA N/A
- PAVM $0.62
- Revenue Growth
- BCDA N/A
- PAVM N/A
- 52 Week Low
- BCDA $1.63
- PAVM $0.55
- 52 Week High
- BCDA $4.66
- PAVM $1.90
- Technical
- Relative Strength Index (RSI)
- BCDA 44.60
- PAVM 42.72
- Support Level
- BCDA $1.98
- PAVM $0.57
- Resistance Level
- BCDA $2.45
- PAVM $0.62
- Average True Range (ATR)
- BCDA 0.16
- PAVM 0.04
- MACD
- BCDA -0.01
- PAVM -0.00
- Stochastic Oscillator
- BCDA 18.00
- PAVM 23.46
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.